Ana T. M.
- Country
- Spain
- Department
- Hematology
Research Overview
- Phase 1 Study of AJ1-11095 in Adults with Myelofibrosis Refractory to JAK2 Inhibitors
- Phase 2 Study of Iadademstat in Patients with Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea
- Phase 3 Randomized Double‑Blind Study of Pelabresib (DAK539) Plus Ruxolitinib vs Placebo + Ruxolitinib in JAK‑Inhibitor‑Naive Adults with Myelofibrosis
Data & Insights
Has run more than one trial at 33 of 124 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in treating various forms of blood cancers, with particular emphasis on diffuse large B cell lymphoma (DLBCL) and chronic myeloid leukemia. Their research encompasses innovative therapeutic approaches for patients with advanced disease states.
- Relapsed/refractory DLBCL management
- Novel therapeutic strategies in CML
- Alternative treatment pathways for transplant-ineligible patients
The investigator's work includes evaluation of targeted therapies for patients who have exhausted standard treatment options.
Blood Disorders
The investigator focuses on myeloproliferative disorders, particularly essential thrombocythemia. Their research explores comparative effectiveness of various treatment modalities for blood disorders.
- Essential thrombocythemia treatment optimization
- Platelet disorder management
- Comparative therapy assessment
Their work extends to investigating novel therapeutic agents for managing blood platelet disorders.
Therapeutic Innovation
The investigator's research portfolio includes evaluation of novel therapeutic compounds and their applications in hematologic conditions. Their work encompasses safety and efficacy assessments of emerging treatments.
- Clinical pharmacology studies
- Safety and tolerability assessments
- Treatment response evaluation
Their investigations focus on developing more effective treatment options for patients with hematologic disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.